OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
662857

Transcenta Holding Ltd

PharmaceuticalsVerified

Transcenta Holding Ltd has a basic and diluted share count of 452,858,499 shares outstanding, indicating no dilution from potential share-based compensation or convertible instruments. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Transcenta, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Transcenta's operations are diversified or concentrated in specific regions or product lines. Growth trajectory data is also absent, with no outlook provided for the current or next fiscal year. The lack of revenue history and forward-looking guidance limits the ability to assess the company's growth potential or market expansion plans. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive events such as share-based compensation or convertible instruments. However, the absence of financial data means that any adjustments or valuation signals from custom valuations are not available for further analysis. Recent events, including filings or transcripts, are not disclosed in the available data. This limits the ability to assess management commentary, strategic shifts, or regulatory developments that may impact the company's operations or valuation.

30-day price · 6628-0.12 (-5.6%)
Low$1.95High$3.06Close$2.04As of12 May, 00:00 UTC
Profile
CompanyTranscenta Holding Ltd
Ticker6628.HK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Transcenta Holding Ltd is a biotechnology company focused on the research, development, and commercialization of innovative therapies in the healthcare sector.

Classification. Transcenta is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Transcenta Holding Ltd has a basic and diluted share count of 452,858,499 shares outstanding, indicating no dilution from potential share-based compensation or convertible instruments. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Transcenta, as the valuation snapshot does not provide data on return on invested capital (ROIC), gross margins, or operating margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Transcenta's operations are diversified or concentrated in specific regions or product lines. Growth trajectory data is also absent, with no outlook provided for the current or next fiscal year. The lack of revenue history and forward-looking guidance limits the ability to assess the company's growth potential or market expansion plans. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive events such as share-based compensation or convertible instruments. However, the absence of financial data means that any adjustments or valuation signals from custom valuations are not available for further analysis. Recent events, including filings or transcripts, are not disclosed in the available data. This limits the ability to assess management commentary, strategic shifts, or regulatory developments that may impact the company's operations or valuation.
Key takeaways
  • Transcenta Holding Ltd has no dilution from basic to diluted shares outstanding.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
  • Profitability and return metrics are not available, making it difficult to benchmark against industry standards.
  • Revenue concentration and geographic exposure are not disclosed, limiting visibility into operational diversification.
  • Growth trajectory and forward-looking guidance are absent, reducing clarity on future performance expectations.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$50.2M-$1.70B-$1.72B-$1.74B
FY-3$101.9M-$366.2M-$406.7M-$373.7M
FY-2$53.8M-$446.8M-$462.6M-$424.5M
FY-1$11.3M-$277.3M-$290.3M-$240.2M
FY0$7.4M-$197.5M-$203.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.54B$1.97B$1.22B
FY-3$2.13B$1.47B$895.5M
FY-2$1.69B$1.03B$546.0M
FY-1$1.20B$751.6M$169.4M
FY0$924.8M$618.1M$14.1M
PeriodOCFCapExFCFSBC
FY-4-$384.5M-$73.3M-$1.74B
FY-3-$295.8M-$22.2M-$373.7M
FY-2-$358.0M-$15.8M-$424.5M
FY-1-$213.8M-$2.3M-$240.2M
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
Metric6628Activity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Observations
IR observations
Mean price target14.40 CNY
Median price target14.40 CNY
High price target14.40 CNY
Low price target14.40 CNY
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.70 CNY
Last actual EPS-0.49 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-13 00:45 UTC#38ed4ff2
Market quoteclose CNY 2.04 · shares 0.45B diluted
no public URL
2026-05-13 00:45 UTC#a480a528
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 01:54 UTCJob: 964beaf7